As per the Attachment.

cr a n:. ® Registered Office: Office No.: 301, 3'" Floor, Konark Icon, Mundhwa-Kharadi Road, Kirtane Baugh, Magarpatta, Hadapsar, Pune, Maharashtra, Pincode-411028. Email: enquiry@cian.co Mobile No.: +919049000648 Website: www.cian.co Corporate Office: 606, Ring Road Mall, Sector-3, Rohini, New Delhi, Pincode-110085. Landline No.: 011-49120841 CIAN HEALTHCARE LIMITED Factory: Khasra No.: 245 & 248, Village Sison a, Bhagwanpur, Roorkee, District Haridwar, Uttarakhand, Pincode-247661. (An ISO 90 01 :2015 & WHO GMP Certified Co.) Mobile No.: +917830655000 CIN: L24233PN2003PLC017563 Ref. No.: CIAN/BSE/2026-27/30 Friday, October 23, 2026 The Manager – Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 542678 Trading Symbol: CHCL Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Approval of Resolution Plan of Dr. Smiths Biotech Private Limited, Wholly Owned Subsidiary of the Company, by the Hon'ble National Company Law Tribunal, and consequent cessation from being a subsidiary of Cian Healthcare Limited. Dear Sir/Madam, In compliance with the relevant provisions of Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations"), and SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, Cian Healthcare Limited (“Company”) hereby inform that Dr. Smiths Biotech Private Limited ("Dr. Smith" or "Corporate Debtor"), a wholly owned subsidiary of the Company, was admitted into the Corporate Insolvency Resolution Process ("CIRP") upon filing of application by Small Industries Development Bank of India (“Financial Creditor”) under the provisions of Section 7 of the Insolvency and Bankruptcy Code, 2016 ("IBC" or “Code”), before the Hon'ble National Company Law Tribunal, Mumbai Bench-III ("NCLT"). The Hon’ble NCLT, vide its order dated September 23, 2026 (“NCLT Order“), approved the resolution plan (“Approved Resolution Plan” or “Plan”) submitted by Ananta Medicare Limited (“Successful Resolution Applicant”), as earlier approved by the Committee of Creditors with unanimous votes, as per the provisions of the Code, on December 25, 2025. In accordance with the relevant provisions of the NCLT Order read with the Approved Resolution Plan, the entire existing equity share capital of Dr. Smith, including the equity shares held by the Company, has been extinguished and cancelled with effect from October 23, 2026, in accordance with the decision taken by the Implementation and Monitoring Committee dated October 23, 2026, which concluded at 03:50 P.M. (IST). The details pursuant to Regulation 30 read with Para A of Part A of Schedule III to the LODR Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are provided in Annexure - A. We shall continue to keep all stakeholders and regulatory authorities abreast of further material developments in this regard. Kindly take the above information on record and oblige. Thanking you, Yours faithfully, For Cian Healthcare Limited Rachit Malhotra Company Secretary & Chief Compliance Officer Membership No.: A39894 Enclosed: As above cr a n:. ® Registered Office: Office No.: 301, 3'" Floor, Konark Icon, Mundhwa-Kharadi Road, Kirtane Baugh, Magarpatta, Hadapsar, Pune, Maharashtra, Pincode-411028. Email: enquiry@cian.co Mobile No.: +919049000648 Website: www.cian.co Corporate Office: 606, Ring Road Mall, Sector-3, Rohini, New Delhi, Pincode-110085. Landline No.: 011-49120841 CIAN H EALTHCARE LIMITED Factory: Khasra No.: 245 & 248, Village Sison a, Bhagwanpur, Roorkee, District Haridwar, Uttarakhand, Pincode-247661. (An ISO 90 01 :2015 & WHO GMP Certified Co.) Mobile No.: +917830655000 CIN: L24233PN2003PLC017563 ANNEXURE A Details pursuant to Regulations 30 read with Para A of Part A of Schedule III to the LODR Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 S. No. Particulars Details Small Industries Development Bank of India filed an application under Section 7 of the Code before the Hon'ble NCLT against Dr. Smiths Biotech Private Limited, which was admitted vide order dated April 28, 2025, thereby initiating the CIRP of Dr. Smith. The Financial Creditor thereafter lodged a claim of INR 8,55,34,648/- (Rupees Eight Crore Fifty-Five Lakh Thirty-Four Thousand Six Hundred and Forty-Eight only) in the CIRP, of Details of any change in which INR 8,47,45,058/- was admitted. (a) the Status/ any development The Hon'ble NCLT, vide the NCLT Order dated September 23, 2026, approved the resolution plan submitted by Ananta Medicare Limited. Pursuant to the implementation of the Approved Resolution Plan, the entire existing equity share capital of Dr. Smith stood extinguished and cancelled on October 23, 2026 and Dr. Smith ceased to be a subsidiary of the Company with effect from that date Based on the audited standalone financial statements of Dr. Smiths Biotech Private Limited and the audited consolidated financial statements of the Company for FY 2025-26: Amount and percentage of the turnover or  Revenue from operations contributed by Dr. Smith: NIL. Total revenue or income and (b) income contributed by Dr. Smith: ₹1.03 lakhs, i.e. 0.03% of the net worth contributed by consolidated total income of ₹2,946.87 lakhs. the subsidiary during  Net worth contributed by Dr. Smith: ₹(987.00) lakhs, i.e. the last financial year (115.63)% of the consolidated net worth of ₹853.60 lakhs. The percentage exceeds 100% because the net worth contributed by Dr. Smith is negative Date on which the Not applicable. The cessation has not arisen from any agreement for sale. (c) agreement for sale has The equity share capital of Dr. Smith has been extinguished and cancelled been entered into by operation of the NCLT Order read with the Approved Resolution Plan. Note applicable, there being no sale or disposal by the Company. Dr. Smith Expected date of ceased to be a subsidiary of the Company with effect from October 23, (d) completion of sale / 2026, upon extinguishment and cancellation of its entire existing equity disposal share capital pursuant to the Approved Resolution Plan. Consideration received Nil. No consideration is receivable by the Company, the equity shares held (e) from such sale / by it in Dr. Smith having been extinguished and cancelled without any disposal payment under the Approved Resolution Plan. Resolution Applicant: Ananta Medicare Limited, a company Brief details of buyers incorporated under the Companies Act, 1956, having its registered office and whether any of the at 621, Ring Road Mall, Sector 3, Rohini, New Delhi – 110085 and CIN buyers belong to the U85110DL2008PLC174677. (f) promoter / promoter group / group The Resolution Applicant is a holding company and a promoter of the companies. If yes, Company and does not belong to the erstwhile promoter group of Dr. details thereof Smiths Biotech Private Limited. cr a n:. ® Registered Office: Office No.: 301, 3'" Floor, Konark Icon, Mundhwa-Kharadi Road, Kirtane Baugh, Magarpatta, Hadapsar, Pune, Maharashtra, Pincode-411028. Email: enquiry@cian.co Mobile No.: +919049000648 Website: www.cian.co Corporate Office: 606, Ring Road Mall, Sector-3, Rohini, New Delhi, Pincode-110085. Landline No.: 011-49120841 CIAN HEALTHCARE LIMITED Factory: Khasra No.: 245 & 248, Village Sison a, Bhagwanpur, Roorkee, District Haridwar, Uttarakhand, Pincode-247661. (An ISO 9001 :2015 & WHO GMP Certified Co.) Mobile No.: +917830655000 CIN: L24233PN2003PLC017563 Whether the transaction No. The cessation arises from the NCLT Order read with the resolution would fall within related plan approved by the Committee of Creditors of Dr. Smith and the Hon’ble (g) party transactions? If NCLT under the IBC and does not involve any transaction between the y [Showing first 8,000 characters — download PDF for full document]